Streetbeat News

Stock Prices

EDIT

Editas Medicine, Inc. (NASDAQ: EDIT) announced its 2024 strategic priorities and anticipated milestones at the J.P. Morgan Healthcare Conference. The company plans to present reni-cel clinical data updates, initiate the RUBY trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue sublicensing its foundational IP. Editas has a strong financial position with a runway into 2026. The company's focus remains on developing reni-cel towards BLA and commercialization, building an in vivo pipeline, and increasing business development activities. Revenue is expected from licensing agreements with Vertex Pharmaceuticals and Vor Bio.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:35 pm

JD

JD.com's stock is trading lower following an internal audit by its subsidiary Dada, which uncovered suspicious practices.

Portfolio Pulse from Luke J Jacobi

January 08, 2024 | 1:35 pm

HRMY

Harmony Biosciences projects 2024 net product revenue between $700M-$720M and has repurchased $50M in common stock in Q4 2023, totaling $100M for the year. The company plans to continue share repurchases in 2024. Key priorities include growing WAKIX for narcolepsy, advancing the pipeline with several trials, and disciplined capital allocation to maximize shareholder value. The financial data is preliminary and unaudited.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:34 pm

EDAP

EDAP TMS SA (NASDAQ:EDAP) announced preliminary results for Q4 2023, reporting a record number of twelve Focal One Systems placements, including ten capital sales. The company also saw a record quarter for sales of ExactVu Micro-Ultrasound systems. The demand came from both academic medical centers and community hospitals. CEO Ryan Rhodes highlighted the momentum of the commercial team and the growing adoption of Focal One in prostate cancer management. Final Q4 financial results are expected in March.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:32 pm

DXLG

Destination XL (DXLG) reported a decrease in total sales to $102.4M during the 9-week holiday sales period ended December 31, 2022, compared to $111.7M in the previous year. The company experienced a comparable sales decline of 8.7%, with a 7.6% decrease in store sales and a 10.9% decrease in direct business sales.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:28 pm

CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) reported preliminary Q4 revenue of $135.4M, surpassing estimates of $127.85M, and full-year 2023 revenue of $482.4M, beating estimates of $474.82M. The company also provided a higher-than-expected 2024 revenue guidance of $600M–$630M, compared to the $513.85M estimate. Additionally, Corcept announced a $200M stock repurchase program. The company's financial growth is attributed to increased treatment rates for Cushing's syndrome with their medication, Korlym.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:28 pm

CME

Barclays analyst Benjamin Budish downgraded CME Group (NASDAQ:CME) from Overweight to Equal-Weight and reduced the price target from $244 to $222.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:27 pm

LABP

Landos Biopharma, Inc. (NASDAQ:LABP) announced that six abstracts on immunometabolism for autoimmune diseases will be presented at the ECCO congress in February 2024. The data includes studies on novel agonists NX-13 and LABP-69, with NX-13 currently in a Phase 2 trial for ulcerative colitis. Topline results are expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:26 pm

ADTX

Trading on ADTX has been halted at 8:25:00 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:25 pm

MKTX

Barclays analyst Benjamin Budish has downgraded MarketAxess Holdings (MKTX) from Overweight to Equal-Weight while increasing the price target from $246 to $291.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:24 pm